Navigation Links
'Fluorescent' Retinal Cells Warn of Eye Disease

Device that measures metabolic stress could help doctors catch trouble early

MONDAY, Feb. 11 (HealthDay News) -- That twinkle in your eye could be an early sign of eye disease if it is seen using a new imaging device developed by scientists at the University of Michigan.

The device detects certain proteins that become fluorescent during the metabolic stress that typically happens at the onset of eye diseases, according to findings published in the February issue of the Archives of Ophthalmology. This flavoprotein autofluorescence (FA) occurs when retinal cells begin to die.

"Autofluorescence occurs when retinal cells begin to die, often the first event in diseases like glaucoma and diabetic retinopathy," study co-author Howard Petty, a biophysicist and expert in imaging with the university's Kellogg Eye Center, said in a prepared statement. "Cell death can be observed microscopically, but not as yet through any current imaging methods. We believe this study is a big step forward, toward creating a diagnostic tool that can characterize disease long before symptoms or visible signs appear."

Many severe eye diseases do not show early symptoms before they begin to diminish vision. Using this device to test a patient is noninvasive and takes less than six minutes, according to the study.

In the study, Petty and fellow researcher Victor M. Elner used the instrument to measure the degree to which a subtle visual condition affected six women. The women had been recently diagnosed with pseudotumor cerebri (PTC), a condition that mimics a brain tumor and often causes increased pressure on the optic nerve that can lead to vision loss.

Because each woman's disease was in a very early stage, the researchers could evaluate how accurately the instrument would detect vision loss as compared to several standard tests used to evaluate vision. In each case, their imaging instrument provided results that were equal to and often superior to the standard tests.

The researchers also found that FA data more accurately described the degree of disease in each patient's eye as compared to the standard vision tests. The patients with PTC had FA values that averaged 60 percent greater in the eye that was more severely affected, the study said. By contrast, an age-matched control group had no significant difference in FA values between their healthy eyes.

"Early treatment for eye disease is so important, and this study suggests that FA activity is a very good indicator of eye disease," Elner, an ophthalmologist and a pathologist, said in a prepared statement. "Cardiologists have long used blood pressure testing to head off heart disease. We believe that FA testing will likewise be a helpful diagnostic tool for eye doctors looking to prevent blindness."

Elner and Petty have patented the device and are investigating its use as a screening device in diabetes and major eye diseases.

More information

The National Eye Institute has more about eye diseases and disorders.

-- Kevin McKeever

SOURCE: University of Michigan Health System, news release, Feb. 11, 2008

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Twinkle after effect can help retinal patients detect vision loss quickly and cheaply
2. Twinkle After-Effect Can Help Retinal Patients Detect Vision Loss Quickly and Cheaply and Prevent Further Loss
3. Transporters may help delay diabetes-related retinal damage
4. Digital Healthcare Announces MacGregor Medical Center San Antonio to Utilize Retasure for Retinal Imaging Assessment
5. Tumors use enzyme to recruit regulatory T-cells and suppress immune response
6. Brain cells work differently than previously thought
7. Embryonic Stem Cells Repair Human Heart
8. Embryonic Human Stem Cells May Help Repair Heart Muscle, Lab Study Shows
9. Circulating fats kill transplanted pancreas cells, study shows
10. Experimental anti-cancer drug made from corn lillies kills brain tumor stem cells
11. Melanoma drug revs immune cells but cancer cells ignore it
Post Your Comments:
Related Image:
'Fluorescent' Retinal Cells Warn of Eye Disease
(Date:11/27/2015)... ... 27, 2015 , ... Indosoft Inc., developer and distributor of ... 11 LTS (Long Term Support) into its Q-Suite 5.10 product line. , Making ... with a version of Asterisk that will receive not only security fixes, but ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... Representative. As a franchise owner, Somu now offers travelers, value and care based ... packages, private cruise sales, as well as, cabin upgrades and special amenities such ...
(Date:11/26/2015)... ... November 26, 2015 , ... WorldCare International, Inc., ... the 61st annual Employee Benefits Conference. The Employee Benefits Conference was hosted by ... through Wednesday, November 11th, 2015. The conference was held at the Hawaii Convention ...
(Date:11/25/2015)... ... November 25, 2015 , ... Additional breast cancers ... on mammography, according to a study published online in the journal Radiology. Researchers ... mammography may necessitate a change in treatment. , Breast MRI is the most ...
(Date:11/25/2015)... ... November 25, 2015 , ... Medical Solutions, one ... for its stellar workplace culture with the company’s Cincinnati office being named a ... Cincinnati office was named a finalist in Cincinnati Business Courier’s 13th annual Greater ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... OAKS, Calif. , Nov. 25, 2015  Amgen ... a Biologics License Application (BLA) with the ... (FDA) for ABP 501, a biosimilar candidate to Humira ... first adalimumab biosimilar application submitted to the FDA and ... pathway. Sean E. Harper , M.D., executive ...
(Date:11/25/2015)... -- On Tuesday, November 24, 2015, the jury ... Medical Technology, Inc. for product liability and misrepresentation ... device, awarded $11 million in favor of Plaintiff ... three days of deliberations, the jury found that ... and unreasonably dangerous, and that Wright Medical made ...
(Date:11/25/2015)... Allergan plc (NYSE: AGN ) today announced that it ... State Attorney General,s Office to end the litigation ... with the Attorney General over the decision of Forest Laboratories, ... the now generic version of memantine immediate release tablets.  Under ... its counterclaims against New York , and ...
Breaking Medicine Technology: